Global Fund Secures Affordable Tuberculosis Test from Cepheid Amid Pressure Campaign
TL;DR Summary
Danaher Corporation has announced an agreement to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at cost to the Global Fund to Fight AIDS, TB and Malaria and less-developed countries eligible for Cepheid's Global Access Program. By reducing the price of the test cartridge to $7.97, Danaher will earn no profit. The agreement expands the partnership between Cepheid and the Global Fund, aiming to improve access to high-quality TB testing in countries where it is most needed. The Global Fund is the largest provider of financing and programs to combat TB globally.
- Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost - Sep 19, 2023 Danaher | Investor Overview
- After a pressure campaign, Cepheid agrees to sell a TB test at cost STAT
- Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses STAT
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
90%
916 → 95 words
Want the full story? Read the original article
Read on Danaher | Investor Overview